A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

What is the purpose of this trial?

CC-90002-ST -001 is an open-label, Phase 1, dose escalation and expansion clinical study in subjects advanced, refractory solid and hematologic cancers.

Participation Guidelines

Ages: 18 years and younger

Gender: Both

Celgene Corporation

Start Date: 09/20/2017

End Date: 01/31/2018

Last Updated: 02/22/2018

Study HIC#: 2000020507